Whitehouse Scientific’s managing director, Jamie Storey, showed his support for ‘Movember’ by joining more than 850,000 fellow ‘Mo Bros’ from around the world in growing facial hair throughout the month of November.
From humble beginnings, ‘Movember’ has become a global campaign aimed at raising vital funds and awareness for men’s health, specifically prostate and testicular cancer. It is one of a number of charity initiatives supported by the Whitehouse Scientific team.
‘Although I have spent the month looking a bit of a fool it was worth it for such a great cause,’ said Storey.
‘With awareness being the key, it was a pleasure explaining why I had grown a handlebar moustache to the many who have asked. I look forward to trying out a new style next year.’
Funds raised by ‘Movember’ in the UK are directed to The Prostate Cancer Charity and Institute of Cancer Research, which supports programmes aimed at increasing early cancer detection, diagnosis and effective treatments, and ultimately reducing the number of preventable deaths.
To date, ‘Movember’ has raised nearly £65m, with £15m coming from the UK. A total of £170m has been collected since 2004.
Whitehouse md grows moustache for charity
Joins fellow ‘Mo Bros’ around the world to raise funds and awareness for men’s health
You may also like
Manufacturing
Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility
The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Research & Development
Simris Biologics secures €200K funding to develop microcystin-based payloads for antibody-drug conjugates
The Berlin-based subsidiary will use the grant to advance the KlicMic R&D programme, creating targeted microcystin payloads for ADCs that aim to improve cancer therapy efficacy whilst reducing side effects
Research & Development
Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness
The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production